Multiple insider buying at IMV (IMV)

Multiple insider buying at IMV (T:IMV)

Albert James Scardino, a Director, acquired 21,315 Common Shares on a direct ownership basis at prices ranging from $3.970USD to $4.080USD between March 29th, 2019 and April 1st, 2019. This represents a $113,756 investment into the company's shares and an account share holdings change of 1.1%.

Pierre Labbé, CFO, acquired 10,000 Common Shares on a direct ownership basis at prices ranging from $5.053 to $5.300 between April 2nd, 2019 and April 3rd, 2019. This represents a $51,807 investment into the company's shares and an account share holdings change of 8.7%.

Frederic Ors, CEO and Director, acquired 2,840 Common Shares on a direct ownership basis at a price of $4.030USD on April 2nd, 2019. This represents a $15,272 investment into the company's shares and an account share holdings change of 2.3%.

Joseph Sullivan, a Senior Officer, acquired 1,350 Common Shares on a direct ownership basis at prices ranging from $3.950USD to $4.000USD between March 29th, 2019 and April 2nd, 2019. This represents a $7,183 investment into the company's shares and an account share holdings change of greater than 100%.

IMV is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

Imv Inc, formerly known as Immunovaccine Inc is a Canada-based clinical-stage immuno oncology company. The Company develops products based on its vaccine enhancement platform with a primary focus on T lymphocytes (T cell) activating therapies for cancer. The Company's DepoVax adjuvanting/delivery platform produces immune response that has a specific and sustained immune effect and enables the Company to pursue vaccine candidates in cancer, infectious diseases and other vaccine applications. The DepoVax platform is used in multiple vaccine candidates, including over two-cancer vaccine candidates that have completed Phase I clinical trials. Its lead cancer vaccine, DPX- Survivac, is tested in a company-sponsored Phase II trial in lymphoma and a Phase Ib trial in ovarian cancer. Its infectious disease vaccine against respiratory syncytial virus (RSV) is in a Phase I clinical trial in Halifax, Nova Scotia.